pharmaceuticals

Last post: June 3rd. See chart. Review: Price was approaching the resistance level. Update: Since the last post, price broke above the resistance level but has failed to stay there and has now fallen back below that level. The breakout was a fake breakout. Conclusion: We need price to break the resistance level again and stay above it before looking for ...

Last post: Feb 28th. See chart. Review: Price had broken a resistance level with a strong move to the upside. Update: Price continued to trend higher but is now in a period of consolidation. Conclusion: We will be waiting for a breakout of the resistance of the consolidation zone before considering a trade. Any comments or questions, do not hesitate to leave ...

Prudent Drug Discovery Company Low market cap (appox £13m at time of writing). Issues shares very rarely (last placing nearly four years ago). Has material interest in its work from larger partners (Pharmaxis). Sold interest in LOXL2 programme for £5m to Pharmaxis in December. Pharmaxis continues to fund and develop LOXL2 inhibitors and Synairgen retains interest ...